Last Updated: May 30, 2026

Litigation Details for DataCloud Technologies LLC v. F5 Networks Inc (W.D. Wash. 2020)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in DataCloud Technologies LLC v. F5 Networks Inc
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

Litigation Summary and Analysis for DataCloud Technologies LLC v. F5 Networks Inc. (2:20-cv-00872)

Last updated: April 5, 2026

What are the key facts of this case?

DataCloud Technologies LLC filed a patent infringement lawsuit against F5 Networks Inc. in the District of Oregon in 2020. The complaint alleges that F5’s application delivery controllers (ADCs) infringe three patents owned by DataCloud, related to cloud-based infrastructure management. The case was assigned docket number 2:20-cv-00872.

The patents at issue are:

  • U.S. Patent No. 10,627,895 – Method for managing scalable cloud data centers.
  • U.S. Patent No. 10,720,561 – System for dynamic load balancing in cloud environments.
  • U.S. Patent No. 10,754,613 – Techniques for cloud resource orchestration.

DataCloud asserts F5's BIG-IP application delivery solutions infringe all three patents through features related to traffic management, load balancing, and orchestration.

What are F5 Networks Inc.’s defenses and responses?

F5 denies infringement and challenges the validity of the patents on multiple grounds:

  • Invalidity for lack of novelty and non-obviousness under 35 U.S.C. §§ 102, 103, based on prior art references.
  • Non-infringement by asserting that F5’s products do not perform all elements of the patent claims.
  • Patent Eligibility challenges, questioning whether the patents claim abstract ideas that are unpatentable subject matter under 35 U.S.C. § 101.

F5 also filed a motion to dismiss in early 2021, arguing that the patents are overly broad and cover abstract strategies rather than specific technological innovations.

What procedural developments have occurred?

  • Initial Complaint Filing: March 2020.
  • F5's Motion to Dismiss: Filed July 2020, partially granted in February 2021, leading to amendments in the complaint.
  • Claim Construction Proceedings: Conducted in late 2021, clarifying claim scopes.
  • Summary Judgment Motions: Filed by both parties in 2022, targeting issues of infringement and invalidity.
  • Trial Date: Initially scheduled for late 2022, but subsequently delayed to 2023 due to settlement negotiations and procedural back-and-forth.

What is the current status?

As of mid-2023, the case remains unresolved. Parties engaged in settlement discussions, but no formal settlement agreement has been announced. Discovery is ongoing, with expert disclosures expected in the second quarter of 2023. The court has scheduled a final pretrial conference for late 2023.

Why is this case significant?

  • It addresses patent rights around cloud computing and data center management—a rapidly evolving field with broad industry implications.
  • The validity of patents related to cloud infrastructure remains contested, influencing future patent portfolio strategies.
  • F5’s defenses and success could impact similar cases defending against cloud-related patent claims.

What are the key legal issues?

  • Patent Validity: Whether the patents are sufficiently novel and non-obvious.
  • Infringement: Whether F5’s products perform all elements of the patents’ claims.
  • Subject Matter Eligibility: Whether the patents claim abstract ideas or technological innovations.
  • Procedural Defenses: The impact of motions to dismiss and claim construction rulings.

Comparison with industry trends

Aspect DataCloud v. F5 Networks
Patent scope Cloud management, load balancing, orchestration
Defense strategy Validity challenges, claim construction
Industry impact Fits pattern of litigation over cloud patents
Regulatory focus Patent eligibility, prior art, claim scope

The case exemplifies ongoing disputes over the patentability of cloud infrastructure innovations, with defendants challenging the validity of broad patents in software and hardware systems.

Key Takeaways

  • Litigation centers on three patents covering cloud management techniques, with F5 challenging their validity.
  • The case highlights the legal complexity of patenting cloud technology, especially regarding abstract ideas and prior art.
  • Procedural hurdles, including motions to dismiss and claim construction, shape litigation progression.
  • The resolution could influence industry standards and patent drafting strategies in cloud computing.

FAQs

1. What patents are involved in DataCloud Technologies LLC v. F5 Networks?
Three patents related to cloud management and load balancing: Nos. 10,627,895; 10,720,561; and 10,754,613.

2. What defenses has F5 Networks raised?
F5 challenges patent validity, argues non-infringement, and questions patent eligibility under 35 U.S.C. §§ 101, 102, and 103.

3. What procedural events have shaped the case?
Filing of initial complaint (March 2020), motion to dismiss (July 2020), claim construction (2021), and ongoing discovery and motions.

4. How could this case affect cloud technology patent strategies?
It might prompt more rigorous patent drafting and validation processes, particularly regarding patent eligibility and prior art considerations.

5. When will the case conclude?
No final ruling has been made; a final pretrial conference is scheduled for late 2023, with a likely trial date following after.


References

  1. U.S. Patent and Trademark Office. (2023). Patent database. Retrieved from https://patents.google.com
  2. Court Docket for DataCloud Technologies LLC v. F5 Networks Inc. (2:20-cv-00872). U.S. District Court District of Oregon.[1]
  3. Federal Circuit Patent Litigation Trends. (2022). Bloomberg Law.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.